EXECUTIVE ENGAGEMENTS
POOL
INTERACTIONS
PARTICIPANTS
VALIDATIONS
COMPANIES
* Login for a full stack data experience
DATE
OCT 2022
TABLES
123
PAGES
196
EDITION
5
PRICE
USD 4950
CODE
MCP16210
*Engagement stats are ongoing and dynamic
HIGHLIGHTS & REPORT INDEX
What's New for 2022?
» Global competitiveness and key competitor percentage market shares
» Market presence across multiple geographies - Strong/Active/Niche/Trivial
» Online interactive peer-to-peer collaborative bespoke updates
» Access to our digital archives and MarketGlass Research Platform
» Complimentary updates for one year
Global Biological Drugs Market to Reach $427.4 Billion by 2027
In the changed post COVID-19 business landscape, the global market for Biological Drugs estimated at US$234.3 Billion in the year 2020, is projected to reach a revised size of US$427.4 Billion by 2027, growing at a CAGR of 9% over the analysis period 2020-2027. Therapeutic Protein, one of the segments analyzed in the report, is projected to record a 10.1% CAGR and reach US$190.5 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Monoclonal Antibody segment is readjusted to a revised 8.3% CAGR for the next 7-year period.
The U.S. Market is Estimated at $69.4 Billion, While China is Forecast to Grow at 8.3% CAGR
The Biological Drugs market in the U.S. is estimated at US$69.4 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$73.8 Billion by the year 2027 trailing a CAGR of 8.3% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.4% and 7.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 7.1% CAGR.
Vaccine Segment to Record 7.4% CAGR
In the global Vaccine segment, USA, Canada, Japan, China and Europe will drive the 7.4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$21.2 Billion in the year 2020 will reach a projected size of US$35.1 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets.
SELECT PLAYERS
Abbott Laboratories; Amgen, Inc.; Baxter International, Inc.; Biogen, Inc.; Bristol-Myers Squibb Company; Eli Lilly and Company; GlaxoSmithKline PLC; Merck & Co., Inc.; Novartis AG; Pfizer, Inc.
SEGMENTS
» Product Type (Therapeutic Protein, Monoclonal Antibody, Vaccine)
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World
TABLE OF CONTENTS
| I. METHODOLOGY |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Influencer Market Insights |
| World Market Trajectories |
| Biological Drugs – Global Key Competitors Percentage Market Share in 2022 (E) |
| Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E) |
| Impact of Covid-19 and a Looming Global Recession |
| 2. FOCUS ON SELECT PLAYERS |
| 3. MARKET TRENDS & DRIVERS |
| 4. GLOBAL MARKET PERSPECTIVE |
| World Recent Past, Current & Future Analysis for Biological Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Biological Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Biological Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Therapeutic Protein by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Therapeutic Protein by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Therapeutic Protein by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Monoclonal Antibody by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Monoclonal Antibody by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Monoclonal Antibody by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027 |
| World Biological Drugs Market Analysis of Annual Sales in US$ Million for Years 2012 through 2027 |
| III. MARKET ANALYSIS |
| UNITED STATES |
| Biological Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E) |
| USA Recent Past, Current & Future Analysis for Biological Drugs by Product Type - Therapeutic Protein, Monoclonal Antibody and Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Biological Drugs by Product Type - Therapeutic Protein, Monoclonal Antibody and Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Biological Drugs by Product Type - Percentage Breakdown of Value Sales for Therapeutic Protein, Monoclonal Antibody and Vaccine for the Years 2012, 2021 & 2027 |
| CANADA |
| Canada Recent Past, Current & Future Analysis for Biological Drugs by Product Type - Therapeutic Protein, Monoclonal Antibody and Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Biological Drugs by Product Type - Therapeutic Protein, Monoclonal Antibody and Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Biological Drugs by Product Type - Percentage Breakdown of Value Sales for Therapeutic Protein, Monoclonal Antibody and Vaccine for the Years 2012, 2021 & 2027 |
| JAPAN |
| Biological Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E) |
| Japan Recent Past, Current & Future Analysis for Biological Drugs by Product Type - Therapeutic Protein, Monoclonal Antibody and Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Biological Drugs by Product Type - Therapeutic Protein, Monoclonal Antibody and Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Biological Drugs by Product Type - Percentage Breakdown of Value Sales for Therapeutic Protein, Monoclonal Antibody and Vaccine for the Years 2012, 2021 & 2027 |
| CHINA |
| Biological Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E) |
| China Recent Past, Current & Future Analysis for Biological Drugs by Product Type - Therapeutic Protein, Monoclonal Antibody and Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Biological Drugs by Product Type - Therapeutic Protein, Monoclonal Antibody and Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Biological Drugs by Product Type - Percentage Breakdown of Value Sales for Therapeutic Protein, Monoclonal Antibody and Vaccine for the Years 2012, 2021 & 2027 |
| EUROPE |
| Biological Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E) |
| Europe Recent Past, Current & Future Analysis for Biological Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Biological Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Biological Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2021 & 2027 |
| Europe Recent Past, Current & Future Analysis for Biological Drugs by Product Type - Therapeutic Protein, Monoclonal Antibody and Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Biological Drugs by Product Type - Therapeutic Protein, Monoclonal Antibody and Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Biological Drugs by Product Type - Percentage Breakdown of Value Sales for Therapeutic Protein, Monoclonal Antibody and Vaccine for the Years 2012, 2021 & 2027 |
| FRANCE |
| Biological Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E) |
| France Recent Past, Current & Future Analysis for Biological Drugs by Product Type - Therapeutic Protein, Monoclonal Antibody and Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Biological Drugs by Product Type - Therapeutic Protein, Monoclonal Antibody and Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Biological Drugs by Product Type - Percentage Breakdown of Value Sales for Therapeutic Protein, Monoclonal Antibody and Vaccine for the Years 2012, 2021 & 2027 |
| GERMANY |
| Biological Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E) |
| Germany Recent Past, Current & Future Analysis for Biological Drugs by Product Type - Therapeutic Protein, Monoclonal Antibody and Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Biological Drugs by Product Type - Therapeutic Protein, Monoclonal Antibody and Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Biological Drugs by Product Type - Percentage Breakdown of Value Sales for Therapeutic Protein, Monoclonal Antibody and Vaccine for the Years 2012, 2021 & 2027 |
| ITALY |
| Italy Recent Past, Current & Future Analysis for Biological Drugs by Product Type - Therapeutic Protein, Monoclonal Antibody and Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Biological Drugs by Product Type - Therapeutic Protein, Monoclonal Antibody and Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Biological Drugs by Product Type - Percentage Breakdown of Value Sales for Therapeutic Protein, Monoclonal Antibody and Vaccine for the Years 2012, 2021 & 2027 |
| UNITED KINGDOM |
| Biological Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E) |
| UK Recent Past, Current & Future Analysis for Biological Drugs by Product Type - Therapeutic Protein, Monoclonal Antibody and Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Biological Drugs by Product Type - Therapeutic Protein, Monoclonal Antibody and Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Biological Drugs by Product Type - Percentage Breakdown of Value Sales for Therapeutic Protein, Monoclonal Antibody and Vaccine for the Years 2012, 2021 & 2027 |
| REST OF EUROPE |
| Rest of Europe Recent Past, Current & Future Analysis for Biological Drugs by Product Type - Therapeutic Protein, Monoclonal Antibody and Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Biological Drugs by Product Type - Therapeutic Protein, Monoclonal Antibody and Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Biological Drugs by Product Type - Percentage Breakdown of Value Sales for Therapeutic Protein, Monoclonal Antibody and Vaccine for the Years 2012, 2021 & 2027 |
| ASIA-PACIFIC |
| Biological Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E) |
| Asia-Pacific Recent Past, Current & Future Analysis for Biological Drugs by Product Type - Therapeutic Protein, Monoclonal Antibody and Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Biological Drugs by Product Type - Therapeutic Protein, Monoclonal Antibody and Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Biological Drugs by Product Type - Percentage Breakdown of Value Sales for Therapeutic Protein, Monoclonal Antibody and Vaccine for the Years 2012, 2021 & 2027 |
| REST OF WORLD |
| Rest of World Recent Past, Current & Future Analysis for Biological Drugs by Product Type - Therapeutic Protein, Monoclonal Antibody and Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of World Historic Review for Biological Drugs by Product Type - Therapeutic Protein, Monoclonal Antibody and Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of World 15-Year Perspective for Biological Drugs by Product Type - Percentage Breakdown of Value Sales for Therapeutic Protein, Monoclonal Antibody and Vaccine for the Years 2012, 2021 & 2027 |
| IV. COMPETITION |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com